drugset / Trial / NCT01520558
CNDO-109-AANK for AML in First Complete Remission (CR1)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a first or second degree relative), after a preparatory chemotherapy regimen, in adult patients with acute myeloid leukemia (AML) who are in their first complete remission at the time of enrollment, are not candidates for stem cell transplant, and are considered to be at high risk for recurrence.
Timeline
- Start
- 2012-12
- Primary completion
- 2016-03
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNDO-109-AANK Cells | Cell therapy | 300000 cells/kg | Other |
| Subject | CNDO-109-AANK Cells | Cell therapy | 1e+06 cells/kg | Other |
| Subject | CNDO-109-AANK Cells | Cell therapy | 3e+06 cells/kg | Other |